Post-transplant lymphoproliferative disease: Association with induction therapy?

Drugs

Volumn 66, Issue 4, 2006, Pages 429-438

  Dharnidharka, Vikas R ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ATG FRESENIUS; BASILIXIMAB; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG HALF LIFE; DRUG MECHANISM; EPSTEIN BARR VIRUS; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LYMPHOPROLIFERATIVE DISEASE; META ANALYSIS; POSTOPERATIVE CARE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

HUMAN HERPESVIRUS 4;

EID: 33645708593     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666040-00003     Document Type: Review

References (54)

1. Green M, Webber S. Posttransplantation lymphoproliferative disorders. Pediatr Clin North Am 2003; 50 (6): 1471-91
2. Nalesnik MA. Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg 1996; 8 (2): 139-48
3. Faye A, Vilmer E. Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options. Paediatr Drugs 2005; 7 (1): 55-65
4. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000; 13 (2): 193-207
5. Jaffe ES, Banks PM, Nathwani B, et al. Recommendations for the reporting of lymphoid neoplasms: a report from the Association of Directors of Anatomic and Surgical Pathology. Mod Pathol 2004; 17 (1): 131-5
6. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14 (2): 214-21
7. Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation 1995; 59: 240-4
8. Dharnidharka VR, Harmon WE. Management of pediatric postrenal transplantation infections. Semin Nephrol 2001; 21 (5): 521-31
9. Rubin RH, Tolkoff-Rubin NE. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother 1993; 37 (4): 619-24
10. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20 (5): 1346-53
11. Dharnidharka VR, Tejani AH, Ho PL, et al. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant 2002; 2 (10): 993-8
12. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003; 76 (6): 984-8
13. Dharnidharka VR. Sirolimus in pediatric solid organ transplantation. Pediatr Transplant 2005; 9 (4): 427-9
14. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351 (26): 2715-29
15. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4 (2): 222-30
16. Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80 (9): 1233-43
17. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323 (25): 1723-8
18. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4 (1): 87-93
19. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76 (9): 1289-93
20. Dharnidharka VR, Stevens G. Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediatr Transplant 2005; 9: 622-6
21. Wilde MI, Goa KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 1996; 51 (5): 865-94
22. Benfield MR, Tejani A, Harmon WE, et al. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation. Pediatr Transplant 2005; 9 (3): 282-92
23. Peraira JR, Segovia J, Fuertes B, et al. Current induction immunosuppression and post-heart transplant lymphoproliferative disorders. Transplant Proc 2003; 35 (5): 2009-10
24. Van Gelder T, Warle M, Ter Meulen RG. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice? Drugs 2004; 64 (16): 1737-41
25. Boggi U, Danesi R, Vistoli F, et al. A benefit-risk assessment of basiliximab in renal transplantation. Drug Saf 2004; 27 (2): 91-106
26. Carswell CI, Plosker GL, Wagstaff AJ. Daclizumab: a review of its use in the management of organ transplantation. Biodrugs 2001; 15 (11): 745-73
27. Chapman TM, Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 2003; 63 (24): 2803-35
28. Onrust SV, Wiseman LR. Basiliximab. Drugs 1999; 57 (2): 207-13, discussion 214
29. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody: United States Simulect Renal Study Group. Transplantation 1999; 67 (2): 276-84
30. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients: CHIB 201 International Study Group. Lancet 1997; 350 (9086): 1193-8
31. Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab: Daclizumab Double Therapy Study Group. Transplantation 1999; 67 (1): 110-5
32. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation: Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338 (3): 161-5
33. Cibrik DM, Kaplan B, Meier-Kriesche HU. Role of anti-interleukin-2 receptor antibodies in kidney transplantation. BioDrugs 2001; 15 (10): 655-66
34. Adu D, Cockwell P, Ives NJ, et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003; 326 (7393): 789
35. Keown P, Balshaw R, Khorasheh S, et al. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation. BioDrugs 2003; 17 (4): 271-9
36. Hanto DW. Association of type of induction with posttransplant lymphoproliferative disorders [letter]. Am J Transplant 2004; 4 (9): 1552
37. Waldmann H, Hale G. CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci 2005; 360: 1707-11
38. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery 2004; 136 (4): 754-60
39. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation: efficacy and safety at five years. Am J Transplant 2005; 5 (6): 1347-53
40. McCurry KR, Iacono A, Zeevi A, et al. Early outcomes in human lung transplantation with thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 2005; 130 (2): 528-37
41. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80 (4): 457-65
42. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353 (8): 770-81
43. Najarian JS, Simmons RL, Condie RM, et al. Seven years' experience with antilymphoblast globulin for renal transplantation from cadaver donors. Ann Surg 1976; 184 (3): 352-68
44. Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 2004; 78 (1): 136-41
45. Brennan DC, Schnitzler MA, Baty JD, et al. A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients. Pharmacoeconomics 1997; 11 (3): 237-45
46. Di Filippo S, Boissonnat P, Sassolas F, et al. Rabbit antithymocyte globulin as induction immunotherapy in pediatric heart transplantation. Transplantation 2003; 75 (3): 354-8
47. Chin C, Pittson S, Luikart H, et al. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation 2005; 80 (4): 477-81
48. Norrby J, Olausson M. A randomized clinical trial using ATG Fresenius or ATG Merieux as induction therapy in kidney transplantation. Transplant Proc 1997; 29 (7): 3135-6
49. Ducloux D, Kazory A, Challier B, et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation 2004; 77 (7): 1029-33
50. Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005; 352 (26): 2705-13
51. Ramos E, Drachenberg CB, Papadimitriou JC, et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13 (8): 2145-51
52. Neumann UP, Neuhaus P. Course and treatment of recurrent hepatitis C after liver transplantation. Minerva Gastroenterol Dietol 2004; 50 (1): 61-6
53. Abbott KC, Bucci JR, Matsumoto CS, et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14 (11): 2908-18
54. United States Renal Data System 2003 report [online]. Available from URL: http://www.usrds.org [Accessed 2006 Feb 24]